S&P 500   4,550.58
DOW   35,430.42
QQQ   389.81
How to trade penny stocks: A step-by-step guide
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
These are the top sectors for blue chip growth in 2024
MercadoLibre up 28% as Latin American ecommerce poised for growth
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
J&J, Gilead, BMS: A look at undervalued dividend payers
The 4 highest-shorted large-cap stocks
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
The JD.com train is getting ready to leave the station again
3 stocking stuffers you can buy for yourself
S&P 500   4,550.58
DOW   35,430.42
QQQ   389.81
How to trade penny stocks: A step-by-step guide
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
These are the top sectors for blue chip growth in 2024
MercadoLibre up 28% as Latin American ecommerce poised for growth
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
J&J, Gilead, BMS: A look at undervalued dividend payers
The 4 highest-shorted large-cap stocks
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
The JD.com train is getting ready to leave the station again
3 stocking stuffers you can buy for yourself
S&P 500   4,550.58
DOW   35,430.42
QQQ   389.81
How to trade penny stocks: A step-by-step guide
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
These are the top sectors for blue chip growth in 2024
MercadoLibre up 28% as Latin American ecommerce poised for growth
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
J&J, Gilead, BMS: A look at undervalued dividend payers
The 4 highest-shorted large-cap stocks
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
The JD.com train is getting ready to leave the station again
3 stocking stuffers you can buy for yourself
S&P 500   4,550.58
DOW   35,430.42
QQQ   389.81
How to trade penny stocks: A step-by-step guide
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
These are the top sectors for blue chip growth in 2024
MercadoLibre up 28% as Latin American ecommerce poised for growth
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
J&J, Gilead, BMS: A look at undervalued dividend payers
The 4 highest-shorted large-cap stocks
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
The JD.com train is getting ready to leave the station again
3 stocking stuffers you can buy for yourself

Veracyte (VCYT) Stock Forecast & Price Target

$25.73
-0.05 (-0.19%)
(As of 11/29/2023 ET)
Compare
Today's Range
$25.60
$26.99
50-Day Range
$19.72
$26.37
52-Week Range
$19.52
$32.40
Volume
652,185 shs
Average Volume
642,094 shs
Market Capitalization
$1.88 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$30.20

Veracyte Consensus Analyst Rating and Stock Price Forecast (2023)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Analysts' Consensus Rating

Moderate Buy
Based on 7 Analyst Ratings

Analysts' Consensus Price Target

$30.20
17.37% Upside
High Forecast$34.00
Average Forecast$30.20
Low Forecast$22.00
TypeCurrent Forecast
11/30/22 to 11/30/23
1 Month Ago
10/31/22 to 10/31/23
3 Months Ago
9/1/22 to 9/1/23
1 Year Ago
11/30/21 to 11/30/22
Consensus Rating
Moderate Buy
Moderate Buy
Moderate Buy
Moderate Buy
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
5 Buy rating(s)
6 Buy rating(s)
4 Buy rating(s)
5 Buy rating(s)
Hold
1 Hold rating(s)
1 Hold rating(s)
1 Hold rating(s)
0 Hold rating(s)
Sell
1 Sell rating(s)
1 Sell rating(s)
1 Sell rating(s)
1 Sell rating(s)
Consensus Price Target$30.20$31.29$30.60$35.17
Predicted Upside17.37% Upside33.54% Upside26.32% Upside48.10% Upside
Get Veracyte Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for VCYT and its competitors with MarketBeat's FREE daily newsletter.


VCYT Analyst Ratings By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

VCYT Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Veracyte Stock vs. The Competition

TypeVeracyteMedical CompaniesS&P 500
Consensus Rating Score
2.57
2.67
2.49
Consensus RatingModerate BuyModerate BuyHold
Predicted Upside17.37% Upside913.00% Upside4,719.85% Upside
News Sentiment RatingNeutral News
Positive News
Positive News

Recent Analyst Ratings and Stock Forecasts

DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
11/10/2023Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetUnderweight ➝ Underweight$23.00 ➝ $22.00-0.90%
11/8/2023Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetBuy ➝ Buy$35.00 ➝ $30.00+29.59%
11/8/2023William Blair
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingOutperform
10/20/2023The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetBuy ➝ Buy$37.00 ➝ $32.00+53.55%
10/10/2023Stephens
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingOverweight ➝ Overweight$34.00+51.52%
1/18/2023Raymond James
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeOutperform ➝ Market Perform
1/4/2023Scotiabank
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageSector Outperform$33.00+38.83%
(Data available from 11/30/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)












VCYT Price Target - Frequently Asked Questions

What is Veracyte's consensus rating and price target?

According to the issued ratings of 7 analysts in the last year, the consensus rating for Veracyte stock is Moderate Buy based on the current 1 sell rating, 1 hold rating and 5 buy ratings for VCYT. The average twelve-month price prediction for Veracyte is $30.20 with a high price target of $34.00 and a low price target of $22.00. Learn more on VCYT's analyst rating history.

Do Wall Street analysts like Veracyte more than its competitors?

Analysts like Veracyte less than other Medical companies. The consensus rating score for Veracyte is 2.57 while the average consensus rating score for medical companies is 2.67. Learn more on how VCYT compares to other companies.

Does Veracyte's stock price have much upside?

According to analysts, Veracyte's stock has a predicted upside of 34.34% based on their 12-month stock forecasts.

What analysts cover Veracyte?

Veracyte has been rated by Morgan Stanley, Needham & Company LLC, Stephens, The Goldman Sachs Group, and William Blair in the past 90 days.


Stock Ratings Reports and Tools

This page (NASDAQ:VCYT) was last updated on 11/30/2023 by MarketBeat.com Staff

My Account -